A detailed history of Fred Alger Management, LLC transactions in Avidity Biosciences, Inc. stock. As of the latest transaction made, Fred Alger Management, LLC holds 17,320 shares of RNA stock, worth $551,122. This represents 0.0% of its overall portfolio holdings.

Number of Shares
17,320
Previous 15,625 10.85%
Holding current value
$551,122
Previous $638,000 24.61%
% of portfolio
0.0%
Previous 0.0%

Shares

11 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

BUY
$37.21 - $48.14 $63,070 - $81,597
1,695 Added 10.85%
17,320 $795,000
Q2 2024

Aug 14, 2024

BUY
$22.73 - $40.85 $355,156 - $638,281
15,625 New
15,625 $638,000
Q2 2023

Aug 14, 2023

SELL
$10.62 - $17.34 $278,711 - $455,070
-26,244 Reduced 16.62%
131,649 $1.46 Million
Q1 2023

May 15, 2023

SELL
$15.35 - $25.65 $280,229 - $468,266
-18,256 Reduced 10.36%
157,893 $2.42 Million
Q4 2022

Feb 14, 2023

BUY
$10.06 - $22.66 $1.77 Million - $3.99 Million
176,149 New
176,149 $3.91 Million
Q1 2022

May 16, 2022

SELL
$14.2 - $23.78 $1.52 Million - $2.55 Million
-107,326 Closed
0 $0
Q4 2021

Feb 14, 2022

BUY
$20.4 - $28.66 $255,428 - $358,851
12,521 Added 13.21%
107,326 $2.55 Million
Q3 2021

Nov 15, 2021

BUY
$18.16 - $25.21 $1.72 Million - $2.39 Million
94,805 New
94,805 $2.34 Million
Q4 2020

Feb 16, 2021

SELL
$24.73 - $35.12 $401,689 - $570,454
-16,243 Closed
0 $0
Q3 2020

Nov 13, 2020

SELL
$23.35 - $35.94 $87,725 - $135,026
-3,757 Reduced 18.79%
16,243 $457,000
Q2 2020

Aug 14, 2020

BUY
$26.62 - $31.5 $532,400 - $630,000
20,000 New
20,000 $565,000

Others Institutions Holding RNA

About Avidity Biosciences, Inc.


  • Ticker RNA
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 52,127,000
  • Market Cap $1.66B
  • Description
  • Avidity Biosciences, Inc., a biopharmaceutical company, engages in the development of oligonucleotide-based therapies. It develops antibody oligonucleotide conjugates (AOC) that are designed to treat a range of serious diseases. The company's lead product candidate AOC 1001 is used for the treatment of myotonic dystrophy type 1, a rare monogenic...
More about RNA
Track This Portfolio

Track Fred Alger Management, LLC Portfolio

Follow Fred Alger Management, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Fred Alger Management, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Fred Alger Management, LLC with notifications on news.